Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Viking Therapeutics initiated a Phase 1 single ascending dose clinical trial for VK3019, a dual amylin and calcitonin receptor agonist, in healthy adults with a BMI of at least 30. The randomized, double-blind study will assess safety, tolerability, and pharmacokinetics, following FDA clearance of the investigational new drug application.
Key figures
- Bmi threshold
- ≥30
- Vk2735 trial duration weeks
- 78
- Preclinical weight reduction pct
- 8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.